Jana Samarin1, Vibor Laketa2, Mona Malz1, Stephanie Roessler1, Ilan Stein3, Elad Horwitz4, Stephan Singer1, Eleni Dimou2, Antonio Cigliano5, Michaela Bissinger1, Christine Susanne Falk6, Xin Chen7, Steven Dooley8, Eli Pikarsky3, Diego Francesco Calvisi5, Carsten Schultz2, Peter Schirmacher1, Kai Breuhahn1. 1. Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. 2. Cell Biology and Cell Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany. 3. Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 4. Department of Developmental Biology and Cancer Research, IMRIC, Hebrew University-Hadassah Medical School, Jerusalem, Israel. 5. Institute of Pathology, University Medicine Greifswald, Greifswald, Germany. 6. Institute of Transplant Immunology, Hannover Medical School MHH, Hannover, Germany. 7. Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA. 8. Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Abstract
UNLABELLED: Transcription factors of the far-upstream element-binding protein (FBP) family represent cellular pathway hubs, and their overexpression in liver cancer (hepatocellular carcinoma [HCC]) stimulates tumor cell proliferation and correlates with poor prognosis. Here we determine the mode of oncogenic FBP overexpression in HCC cells. Using perturbation approaches (kinase inhibitors, small interfering RNAs) and a novel system for rapalog-dependent activation of AKT isoforms, we demonstrate that activity of the phosphatidylinositol-4,5-biphosphate 3-kinase/AKT pathway is involved in the enrichment of nuclear FBP1 and FBP2 in liver cancer cells. In human HCC tissues, phospho-AKT significantly correlates with nuclear FBP1/2 accumulation and expression of the proliferation marker KI67. Mechanistic target of rapamycin (mTOR) inhibition or blockade of its downstream effector eukaryotic translation initiation factor 4E activity equally reduced FBP1/2 concentrations. The mTORC1 inhibitor rapamycin diminishes FBP enrichment in liver tumors after hydrodynamic gene delivery of AKT plasmids. In addition, the multikinase inhibitor sorafenib significantly reduces FBP levels in HCC cells and in multidrug resistance 2-deficient mice that develop HCC due to severe inflammation. Both FBP1/2 messenger RNAs are highly stable, with FBP2 being more stable than FBP1. Importantly, inhibition of phosphatidylinositol-4,5-biphosphate 3-kinase/AKT/mTOR signaling significantly diminishes FBP1/2 protein stability in a caspase-3/-7-dependent manner. CONCLUSION: These data provide insight into a transcription-independent mechanism of FBP protein enrichment in liver cancer; further studies will have to show whether this previously unknown interaction between phosphatidylinositol-4,5-biphosphate 3-kinase/AKT/mTOR pathway activity and caspase-mediated FBP stabilization allows the establishment of interventional strategies in FBP-positive HCCs.
UNLABELLED: Transcription factors of the far-upstream element-binding protein (FBP) family represent cellular pathway hubs, and their overexpression in liver cancer (hepatocellular carcinoma [HCC]) stimulates tumor cell proliferation and correlates with poor prognosis. Here we determine the mode of oncogenic FBP overexpression in HCC cells. Using perturbation approaches (kinase inhibitors, small interfering RNAs) and a novel system for rapalog-dependent activation of AKT isoforms, we demonstrate that activity of the phosphatidylinositol-4,5-biphosphate 3-kinase/AKT pathway is involved in the enrichment of nuclear FBP1 and FBP2 in liver cancer cells. In humanHCC tissues, phospho-AKT significantly correlates with nuclear FBP1/2 accumulation and expression of the proliferation marker KI67. Mechanistic target of rapamycin (mTOR) inhibition or blockade of its downstream effector eukaryotic translation initiation factor 4E activity equally reduced FBP1/2 concentrations. The mTORC1 inhibitor rapamycin diminishes FBP enrichment in liver tumors after hydrodynamic gene delivery of AKT plasmids. In addition, the multikinase inhibitor sorafenib significantly reduces FBP levels in HCC cells and in multidrug resistance 2-deficient mice that develop HCC due to severe inflammation. Both FBP1/2 messenger RNAs are highly stable, with FBP2 being more stable than FBP1. Importantly, inhibition of phosphatidylinositol-4,5-biphosphate 3-kinase/AKT/mTOR signaling significantly diminishes FBP1/2 protein stability in a caspase-3/-7-dependent manner. CONCLUSION: These data provide insight into a transcription-independent mechanism of FBP protein enrichment in liver cancer; further studies will have to show whether this previously unknown interaction between phosphatidylinositol-4,5-biphosphate 3-kinase/AKT/mTOR pathway activity and caspase-mediated FBP stabilization allows the establishment of interventional strategies in FBP-positive HCCs.
Authors: Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet Journal: Gastroenterology Date: 2008-08-20 Impact factor: 22.682
Authors: Mona Malz; Michael Bovet; Jana Samarin; Uta Rabenhorst; Carsten Sticht; Michaela Bissinger; Stephanie Roessler; Justo Lorenzo Bermejo; Marcus Renner; Diego Francesco Calvisi; Stephan Singer; Matthias Ganzinger; Achim Weber; Norbert Gretz; Martin Zörnig; Peter Schirmacher; Kai Breuhahn Journal: Hepatology Date: 2014-07-31 Impact factor: 17.425
Authors: Cyprian D Cukier; David Hollingworth; Stephen R Martin; Geoff Kelly; Irene Díaz-Moreno; Andres Ramos Journal: Nat Struct Mol Biol Date: 2010-08-15 Impact factor: 15.369
Authors: J Y Liu; Q H Zeng; P G Cao; D Xie; F Yang; L Y He; Y B Dai; J J Li; X M Liu; H L Zeng; X J Fan; L Liu; Y X Zhu; L Gong; Y Cheng; J D Zhou; J Hu; H Bo; Z Z Xu; K Cao Journal: Oncogene Date: 2018-04-17 Impact factor: 9.867